On April 19, AMCP submitted joint recommendations to CMS on Medicare Advantage enrollees seeking COVID-19 vaccine without their Original Medicare card. CMS is recommended to present clear guidance to all vaccination sites and providers and instruct MACs to provide assistance to providers to ensure vaccine administration is accurately reimbursed and entered into the COVAX portal.
AMCP submitted a letter on the reopened comment period for the Medicaid Coverage of Innovative Technologies rule, which created a pathway for fast national Medicare coverage of innovative technologies, including digital therapeutics.
On March 16, AMCP joined Medicare stakeholders in urging House and Senate leadership to swiftly repeal the 2020 Medicare Part D rebate rule using Congressional Review Act authority.
On Feb. 18, AMCP joined the Modern Medicaid Alliance in urging Congress to strengthen the Medicaid program in the next COVID response bill by increasing the Federal Medical Assistance Percentage (FMAP) by at least 12 percentage points.
AMCP submitted comments to CMS on the Most Favored Nation Model rule, expressing our significant concerns that the model would negatively impact patient access to needed medications.
Read AMCP's summary of how the inauguration of the Biden administration may lead to changes to reglatory actions taken at the end of the Trump administration.
In a January 15th letter to President-elect Joseph R. Biden, AMCP shared its priority issues related to the COVID-19 pandemic and managed care pharmacy.
